ABPRO Holdings Inc
NASDAQ:ABP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ABPRO Holdings Inc
Net Income (Common)
ABPRO Holdings Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ABPRO Holdings Inc
NASDAQ:ABP
|
Net Income (Common)
-$17.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alumis Inc
NASDAQ:ALMS
|
Net Income (Common)
-$243.3m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Grail Inc
NASDAQ:GRAL
|
Net Income (Common)
-$408.4m
|
CAGR 3-Years
58%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Oruka Therapeutics Inc
NASDAQ:ORKA
|
Net Income (Common)
-$105.4m
|
CAGR 3-Years
-120%
|
CAGR 5-Years
-61%
|
CAGR 10-Years
-25%
|
|
|
Rapport Therapeutics Inc
NASDAQ:RAPP
|
Net Income (Common)
-$111.5m
|
CAGR 3-Years
-119%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Metsera Inc
NASDAQ:MTSR
|
Net Income (Common)
-$209.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ABPRO Holdings Inc
Glance View
ABPRO Holdings Inc is a US-based company operating in industry. The company is headquartered in New York City, New York. The company went IPO on 2022-01-14. Abpro Holdings, Inc. is a biotechnology company dedicated to developing next-generation antibody therapeutics, which helps in improving the lives of patients with severe and life-threatening diseases. The firm is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its DiversImmune and MultiMab antibody discovery and engineering platforms, it is engaged in developing a pipeline of antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2 (HER2), and cluster of differentiation 3 (CD3), T-cell co-receptor.
See Also
What is ABPRO Holdings Inc's Net Income (Common)?
Net Income (Common)
-17.4m
USD
Based on the financial report for Dec 31, 2024, ABPRO Holdings Inc's Net Income (Common) amounts to -17.4m USD.
What is ABPRO Holdings Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
-49%
Over the last year, the Net Income (Common) growth was -49%.
